Kventiax (Quetiapine)

Quetiapine blocks serotonin 5‑HT2A and dopamine D2 receptors while partially stimulating 5‑HT1A receptors. This combined antagonism and partial agonism reduces excessive dopamine and serotonin activity, leading to antipsychotic, mood‑stabilising and antidepressant effects without full dopamine blockade.

The specific dose of Kventiax is determined by the prescribing clinician based on the patient’s diagnosis, severity of symptoms, age, renal and hepatic function, and other individual factors. Only a qualified health professional should set the appropriate dosing regimen.

Safety data for quetiapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Kventiax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Kventiax (quetiapine) offers a broader receptor profile, including strong antihistamine and α1‑adrenergic blockade, which can lead to greater sedation and metabolic effects compared with some alternatives. Its partial 5‑HT1A agonism may provide additional mood‑stabilising benefits, but individual response varies and should be assessed by a clinician.

Kventiax should be stored at room temperature, below 25 °C (77 °F). Keep the tablets in their original packaging, protect them from moisture, heat and direct sunlight, and ensure they are out of reach of children.

Kventiax is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed. Dosing frequency and titration are individualized based on therapeutic response and tolerability.

Serious risks include neuroleptic malignant syndrome, severe hypotension, agranulocytosis, cardiac arrhythmias, and increased suicidal thoughts, especially in young adults. Patients should be monitored closely for fever, muscle rigidity, sudden blood pressure changes, signs of infection, or emergent mood changes.

Kventiax is contraindicated in patients with known hypersensitivity to quetiapine or any excipients, and in individuals with a history of severe cardiovascular disease where orthostatic hypotension could be hazardous. Caution is also advised for patients with uncontrolled diabetes, severe hepatic impairment, or those taking interacting medications.